Home » Economy » Pharma – Treatment of lung cancer: Roche reports positive study data News

Pharma – Treatment of lung cancer: Roche reports positive study data News

Wednesday, September 6th, 2017 | Economy

In the study, patients with ALK-positive, advanced non-small-cell lung cancer (NSCLC) were treated with alecensa who had progressed after platinum-based chemotherapy and crizotinib, according to a Wednesday media release.
Alecensa had better results than chemotherapy, Roche continues. In 85% of treated patients, the time when the disease was not progressed (progression-free survival (PFS)) was longer in treatment with Alecensa.
According to Roche, the median PFS, the primary endpoint of the study, was 9.6 months for Alecensa patients compared to 1.4 months for those who received chemotherapy.
An independent audit committee identified a median PFS of 7.1 months for Alecensa versus 1.6 months for chemotherapy. This was the secondary endpoint of the study.
Roche wants to present the detailed study dates for the coming weekend at the European Society for Medical Oncology (ESMO).
(AWP)

Related

Deutsche Telekom: router hacker gets pro

The hacker responsible for the failure of more than one million telecom routers

Bol d'Or 2017: GMT94 wins before Pen

17. September 2017 – 17:45 EWC World Champion GMT94 Yamaha wins the Bol

"The SPD has said it does not want

Another four weeks to the Bundestag election and the race seems already decided.

Social Media: German Influencers adverti

A photo with the supposedly favorite make-up, a photo in the supposedly favorite